CPHI South East Asia 2025
July 16-18, 2025
Kuala Lumpur, Malaysia
https://www.cphi.com/sea/en/home.html
News and Events
Subscribe to our press distribution list to receive the latest news about AMW.
Upcoming
Events
CPHI 2025
October 28-30, 2025
Frankfurt, Germany
https://www.cphi.com/europe/en/home.html
BIO-Europe 2025
November 3-5, 2025
Vienna, Austria
https://informaconnect.com/bioeurope/
Past
Events
Archive
Pharmapack
January 24-25, 2024 Paris, France https://www.pharmapackeurope.com/
read morePharmasynergy
February 08-09, 2024
London, UK
euroPLX84
February 26-27, 2024 Lisbon, Portugal
read moreBIO-Europe Spring
March 18-20, 2024
Barcelona, Spain
https://informaconnect.com/bioeurope-spring/
4th Wet AMD & Diabetic Eye Disease Drug Development
March 19-21, 2024
Boston, MA
https://wet-amd-drug-development.com/
BIO International Convention
June 03-06, 2024
San Diego, California
https://www.bio.org/events/bio-international-convention
CPHI South East Asia
July 10-12, 2024 Bangkok, Thailand https://www.cphi.com/sea/en/home.html
read moreCPHI 2024
October 08-10, 2024 Milan, Italy https://www.cphi.com/europe/en/home.html
read morePODD – Partnership Opportunities in Drug Delivery
October 28-29, 2024 Boston, USA https://poddconference.com
read moreBIO-Europe
November 04-06, 2024 Stockholm, Sweden https://informaconnect.com/bioeurope/
read morePharmaSynergyRx 2025
February 27-28, 2025
London, UK
https://pharma-synergy-conference.com/pharmasynergy-2025/
BIO-Europe Spring
March 17-19, 2025
Milan, Italy
https://informaconnect.com/bioeurope-spring/
DCAT Week 2025
March 17-20, 2025
New York City, USA
https://dcatweek.org/
AT Uro Congress
May 22-24, 2025
Vienna, Austria
EuroPLX
June 2-3, 2025
Lisbon, Portugal
Latest
News
AMW GmbH realigns management
Dr. Wilfried Fischer, founding shareholder of AMW, has retired from the management board and remains associated with the company as an important shareholder. His areas of responsibility will be taken over by the previous Co-Managing Directors Dr. Friedrich Tegel and Philipp Karbach.
read moreAMW GmbH from Warngau continues to grow and establishes an advisory board
More than 100 people are now employed at the pharmaceutical plant in Warngau. In addition to the implants Goserelin and Leuprorelin and the patches Buprenorphin and Rivastigmine, the specialty pharmaceutical company developed a generic version of MSD’s Nuvaring contraceptive ring to market maturity. AMW is thus setting new standards in contraception. In order to improve its scientific and technical position, AMW has established an advisory board consisting of Dr. Georg Ingram, Dr. Dirk Schrader and Prof. Dr. Gerhard Winter.
read moreBrussels, 21 December 2017: Investment Plan for Europe: EIB lends to AMW GmbH in Warngau
The European Investment Bank (EIB) is providing EUR 25 million to AMW GmbH (AMW). AMW is a specialist pharmaceutical company that specializes in novel drug delivery systems. With the money, AMW will be able to expand the development of innovative medicines, carry out clinical trials and expand its production capacity at its plant in Warngau in Upper Bavaria as well as at its subsidiary Endomedica (Halle, Saxony-Anhalt). A new building for research, development and production with special manufacturing technology and state-of-the-art laboratory equipment is to be built at the company headquarters in Warngau.
read moreEndomedica GmbH, our wholly owned subsidiary based in Halle, was able to present itself to a wide audience including well-known pharmaceutical companies and investors from the fields of biotechnology and medical technology at the Health Innovation Summit on 11.7.2017.
The event took place simultaneously as a webinar in Munich, Tokyo and Silicon Valley and allowed discussion rounds after the presentation.
read moreOn 22 June 2017, the AMW received a high visit from the Bavarian Minister of Economic Affairs and Deputy Prime Minister of the Free State of Bavaria.
Within this framework, the pharmaceutical plant was able to present itself as the largest training company in Warngau.
read more